This phase I study is seeking to evaluate the safety of increasing radioactive dose levels of 131I-TLX101 when given in addition to best standard of care treatment in people with newly diagnosed glioblastoma.
This trial is treating patients with glioblastoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had a certain type of treatment or surgical procedure.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1 Safety and Dose Finding Study of 131I -TLX101 Plus Standard of Care in Patients With Newly Diagnosed Glioblastoma
Telix International Pty Ltd
Eligible participants will receive 131I-TLX101, administered via intravenous infusion in ascending doses, as well as 18F-FET, also administered intravenously.
Recruiting Hospitals Read More